Michael Kemper, MD
Urology · Decatur, GANPI 1255746871
Payments from drug & device makers
What this record shows
This record is dominated by grants: $50,000 of the $72,439 with a category attached, or 69.0%. Boston Scientific accounts for 79.9% of it on its own, with 42 other manufacturers making up the rest. Reporting peaked in 2019 at $53,939 and has fallen 96.3% since, to $1,995 in 2025. Among urology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 416 payments — averaging $174.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$58K
- Coloplast$4K
- Teleflex LLC$3K
- Axonics, Inc.$2K
- Endo Pharmaceuticals Inc.$1K
- Astellas Pharma US Inc$611
- plus $4K from 37 others
What the payments were for
- Grants$50,00069%
- Travel & lodging$4,8897%
- Food & beverage$17,42124%
- Education$1290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL ERECTILE DYSFUNCTION$50,399
- TITAN$2,680
- UroLift System$1,802
- AMS$1,426
- AMS 700 CXR RTE KIT$871
- UroLift$854
- Bulkamid$804
- AMS 700$738
- XIAFLEX$570
- Axonics$542
- GENERAL BPH$422
- GreenLight XPS$277
- Axonics r-SNM System$232
- Barrigel$181
- GENERAL - THERAPIES$175
- UroCuff$154
- REZUM$148
- eCoin Device Kit$139
- SpaceOAR VUE System - 10mL$136
- Coloplast TFL Drive$134
How this compares
$72,439 in reported general payments places this provider in the 95th percentile of 369 urology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 73 | $1,060,163 |
| NubeqaDarolutamide | 32 | $421,322 |
| XtandiEnzalutamide | 18 | $280,319 |
| MyrbetriqMirabegron | 87 | $105,900 |
| GemtesaVibegron | 93 | $83,455 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 230 | $4,606 |
| Tamsulosin Hcl | 420 | $4,421 |
| Dutasteride | 82 | $3,975 |
| Tolterodine Tartrate ErTolterodine Tartrate | 36 | $2,514 |
| Solifenacin Succinate | 47 | $1,972 |
| Estradiol | 25 | $1,614 |
| Trospium Chloride | 33 | $1,529 |
| Methenamine Hippurate | 17 | $1,435 |
| Tolterodine Tartrate | 14 | $1,168 |
| Testosterone Cypionate | 21 | $1,137 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $225 | $1,060,16373 claims |
| BayerNubeqa | $406 | $421,32232 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $611 | $386,219105 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $305 | $83,45593 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 369 urology providers in Georgia.
Other urology in Decatur
- Daniel CanterDecatur$329K
- Hemant ChaparalaDecatur$33K
- Syed JafriDecatur$21K
- Vahan KassabianRoswell$1.6M
- Lewis KritemanRoswell$864K
- Tariq HakkyAtlanta$140K
- Sherita KingAugusta$108K
- Brittani Barrett-HarlowFayetteville$100K
- James BennettAtlanta$93K
- Anthony BarnesAtlanta$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.